How to Conduct Post-Market Surveillance for Overseas Registration of Dental Devices?

Post-market surveillance (PMS) is a continuous compliance obligation that does not end with obtaining a registration certificate. To remain compliant, dental device manufacturers must first determine whether the product is within the regulatory scope of the target country, identify the registration pathway and applicant based on risk classification, and assess the reusability of existing NMPA, CE, FDA, and ISO 13485 documentation. A proactive PMS system includes adverse event reporting, product change control, label and instruction manual review, customer complaint handling, and periodic risk re-evaluation. Reporting obligations through a local agent or authorized representative must be fulfilled according to applicable local regulations.

Key Summary

Overseas registration for dental devices is not a one-time event. After a certificate is obtained, manufacturers must maintain active PMS to ensure continued compliance. The first step is to confirm whether the target country regulates the device as a medical device, then determine the appropriate registration pathway based on risk classification. Existing documentation from NMPA, CE, FDA, ISO 13485, or other markets should be mapped for reuse. A robust PMS system should include adverse event reporting, change control, label and IFU verification, complaint handling, and periodic risk reassessment. All reporting obligations to local authorities must be executed through a local agent or authorized representative.

Common risks include neglecting change notifications, which may invalidate the registration certificate, and failing to submit PSURs or annual updates as required by local regulations. Companies are advised to embed PMS into their quality management system, designate responsible persons, and maintain a complete evidence trail to support regulatory inspections and certificate renewals.

Applicable Scenarios and Core Issues

After receiving overseas registration approval, many companies incorrectly assume that no further action is required. In reality, regulators in most countries require the registrant to continue fulfilling post-market obligations and may conduct unannounced inspections, document reviews, or sampling at any time. PMS applies from the moment the product is placed on the market in the target country until the certificate expires or is withdrawn, covering every stage in between.

The core question is not whether to conduct PMS but rather under what rules it should be conducted, who is responsible, and what evidence must be retained. Requirements vary significantly by country. For example, the EU MDR underlines systematic PMS systems, the FDA emphasizes MDR reporting and annual registration updates, and countries in Southeast Asia and the Middle East often rely on local agents for information transmission and change filing. If a company merely translates domestic procedures without adapting them, gaps will likely surface during inspections.

PMS is also triggered by design changes, material changes, production site changes, user complaints, adverse events, recalls, safety alerts, or certificate renewal requests. In such situations, the registrant must assess whether changes affect the registration certificate and whether supplementary applications or notifications are required in each country.

Registration Determination Logic

Establishing a correct PMS mechanism requires a solid understanding of the registration determination logic, because the scope of post-market obligations depends on the nature of the initial approval. The first step is to verify whether the product is regulated as a medical device in the target country. Dental devices range from handpieces, ultrasonic scalers, and root canal instruments to implants, restorative materials, and impression materials. Some are active devices, others are non-active implantable or non-implantable, and many fall under in vitro diagnostics. Classification varies by jurisdiction.

The second step is to determine the risk class and registration pathway. In GHWP member countries and systems with similar classification, dental devices typically fall into Class I, II, or III based on risk. The registration method, review intensity, and post-market obligations differ by class. Some countries allow Class I devices to be self-declared, while Class III devices often require rigorous clinical evaluation and quality system audits, along with periodic safety and performance updates.

Third, assess the reusability of existing documentation. Companies should inventory NMPA registration files, CE technical documentation, FDA 510(k) or PMA submissions, ISO 13485 or MDSAP certificates, and other market evidence to determine whether these can support the PMS framework in the target country. If reusable, duplication is reduced. However, clinical evaluation, biological evaluation, risk management, and labeling must meet target-country requirements and cannot be directly copied.

Fourth, confirm specific obligations related to technical files, performance validation, risk management, clinical evaluation or evidence, labeling, local agent and authorized representative roles, and post-market maintenance. For multi-country registrations, including GHWP members, core technical files can be reused, but localization is essential—including language, regulatory references, test standards, clinical indications, and contraindications. The PMS system should be built on this unified foundation and then customized to each country's reporting process.

Documentation and Evidence

PMS is not merely keeping a few records. It requires a complete evidence chain demonstrating ongoing compliance. Essential documentation includes: registration certificate or market authorization and its annexes; original and localized labels and IFUs; technical files and all change records; risk management reports and updates; quality management system documents; product test reports and clinical evaluation reports; adverse event reports and complaint handling records; product recall or notification records; periodic safety update reports; and local agent or authorized representative agreements and communication logs.

Technical files should include a product description, intended use, working principles, key performance indicators, material composition, manufacturing process, sterilization or packaging validation, shelf life, and transport stability testing. During changes, version control must clearly record the date, content, assessment conclusion, and whether regulatory notification is needed. Risk management reports should be updated based on adverse events, customer feedback, and scientific literature, with risk levels raised or controls added when necessary.

Labels and IFUs are focal points for post-market inspection. Different countries have specific requirements for symbols, language, contraindications, warnings, storage conditions, and expiration dating. Companies should establish a label review procedure to ensure every update is reviewed for regulatory compliance and that all market-specific versions are replaced. With local agents, agreements must be maintained, including scope of authorization and records of forwarded communications, to avoid information gaps.

For GHWP multi-country registrations, companies should maintain a global registration status table showing certificate numbers, expiry dates, agent contact details, renewal deadlines, and the types and due dates of periodic reports. This table serves as an internal management tool and as the foundation for responding to regulatory inquiries or customer audits.

Common Mistakes

• Assuming the registration certificate is valid indefinitely and neglecting renewal or annual updates. Many countries issue certificates valid for 2–5 years, and failure to renew can lead to product suspension.
• Lack of change management, especially when design or manufacturing process changes are not reported to regulators, resulting in the marketed product differing from registered details.
• Merely recording adverse events without reporting them within required deadlines. Some countries require serious adverse event reporting within 10–30 days; late reporting triggers penalties.
• Delegating all PMS tasks to sales or agents without an internal regulatory function and designated responsible individuals, creating a vacuum of accountability.
• Using labels and IFUs only in Chinese or English without localization to the target country's language, which hampers regulatory review and on-site inspections.
• Failing to regularly collect and evaluate customer feedback, complaints, and repair records, thus missing early signals of potential safety issues.
• Insufficient clinical evaluation awareness. After a major product change, clinical evidence may no longer be sufficient, but companies forget to reassess.
• Records are incomplete or version-controlled poorly, so the evidence chain fails during inspections, damaging credibility and certificate status.

Company Preparation Checklist

• Establish a cross-functional PMS team covering regulatory, quality, R&D, production, sales, and after-sales, with clear roles and responsibilities.
• Develop PMS procedures and work instructions covering adverse event reporting, complaint handling, change control, and annual review.
• Maintain a global registration ledger with certificate numbers, validity periods, agent information, regulatory authority contacts, and submission deadlines.
• Establish a change assessment system so any change to product design, process, raw materials, labeling, or production site triggers review.
• Define an adverse event reporting process with internal notification timelines, seriousness assessment criteria, and methods for informing regulators and agents.
• Prepare and maintain reusable core technical files, localized for each target country.
• Sign clear agreements with local agents specifying duties, response times, and communication channels for regulatory information and emergency reporting.
• Conduct regular internal audits or mock inspections to verify the effectiveness of the PMS system and drive continuous improvement.

AIMEILI Perspective

Many companies mistakenly treat overseas registration as a one-off project and assume that no work is required until renewal. However, regulators are increasingly conducting ongoing compliance reviews, particularly after adverse events, often checking whether the company has maintained a full PMS record. Without a pre-established system, companies may scramble to create documents under pressure, resulting in poor-quality evidence and even suspicion of systemic non-compliance.

The right time to build a global PMS framework is during the feasibility analysis, not after the product starts selling. Companies should evaluate post-market obligations of each target country at the same time as they assess registration feasibility, and incorporate adverse event reporting deadlines, change notification requirements, periodic safety update reports, and renewal cycles into the registration budget and project plan. This approach prevents budget overruns and speeds up market entry.

Document reuse must distinguish between what can be reused and what must be localized. ISO 13485 certificates, MDSAP certificates, performance test data, and baseline risk management files are often reusable, but clinical evaluation conclusions, labeling, registration application forms, and applicable standards lists usually need country-specific adjustments. Avoid simply translating domestic or EU labels into local languages—indications, contraindications, and warnings may require review under the local regulatory framework.

Local agents and certificate control are lifelines for PMS. The company must ensure a clear authorization and control relationship between the legal entity holding the certificate and the local agent. Some companies rely entirely on dealers who are not equipped to transmit regulatory information, causing missed change requirements or renewal notices. When signing with an agent, companies should include IP and certificate ownership clauses and require the agent to forward regulatory correspondence within one working day.

For multi-country registration, companies should build a unified product master file and a country-specific regulatory difference list to reduce rework. A shared database should record submitted document versions, review comments, rectification content, and final approvals per country. When a change occurs, the same change assessment form can be used to determine whether notifications are required across all markets, avoiding isolated information. This approach reduces workload and ensures consistency across markets, giving management a clear view of global compliance status.

Common Follow-up Questions

How do I renew a dental device registration certificate?

Renewal requirements vary by country, but typically you must submit a renewal application 6–12 months before expiry. This includes updated technical files, labels and IFUs, quality management system certificates, adverse event and complaint summaries, and a product change history. You will also need to pay the relevant fees. Some countries require a periodic safety update report or clinical data summary to demonstrate continued safety and effectiveness. Contact your local agent early to confirm the checklist and allow time for translation, notarization, and corrections.

Do I need a new registration after a design change?

First, identify whether the change affects product safety and essential performance. If there are changes to intended use, working principle, major raw materials, critical process, sterilization method, or shelf life, a change application or supplementary submission is usually required. For minor cosmetic or packaging size changes that do not affect safety or regulatory requirements, an internal update and notification to the agent may suffice. When planning a change, review the change guidelines of each country and document your assessment.

What is the timeline for adverse event reporting?

Deadlines vary by jurisdiction. Under most frameworks, serious adverse events must be reported within 10 to 30 days of confirmation. Some countries require shorter timelines for life-threatening risks or unexpected events. Minor events are typically summarized in annual updates. Companies should have an internal initial report mechanism within 24 hours and begin investigation immediately upon awareness. If uncertain whether an event is reportable, err on the side of reporting and consult your local agent or regulatory advisor.

Further Reading

• How to Conduct Post-Market Surveillance for Overseas Registration of Monitoring Devices?
• What Are the Risk Management File Requirements for Implantable Product Overseas Registration?
• How to Organize Technical Files for Dental Device Overseas Registration?
• Can Test Reports Be Reused for Dental Device Overseas Registration?
• How to Use an ISO 13485 Certificate in Dental Device Overseas Registration?
• What Are the Risk Management File Requirements for Dental Device Overseas Registration?

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Preference is given to official regulatory bodies, international organizations, standard organizations, and public regulation materials; industry media and project experience are only used as auxiliary judgment. Applicability boundary: This article is intended for early comprehension, document preparation, and project planning. It does not replace formal requirements, testing conclusions, or legal opinions issued by target-country regulatory authorities.